News and Announcements
Leaf Resources Final Report & Shareholder Update
- Published September 08, 2016 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
30th September 2016, ASX Announcement
The last 12 months has been a period of significant progress for Leaf Resources as we are now in an ideal position to capitalise on the global shift away from traditional petrochemical manufacturing towards a more sustainable future.
Highlights for the year include the Claeris transaction and possible opportunities at ZeaChem’s Boardman facility, which are detailed below.
Claeris
A new era for Leaf Resources was marked with the announcement of a joint venture (JV) agreement with US-based project developer Claeris LLC in July 2016. Claeris is a world-class project developer , based in Dallas, Texas, with a track record of delivering large-scale, financially successful, renewable projects.
To view the full Report, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
